People · Operator
Named in public records as an officer, director or promoter · active 2013–2026 · Biotechnology, Biotech / Pharma, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vizgen, Inc. | — | Biotechnology | Series D+ | $295.1M | $319.9M | 2021 |
| Arbor Biotechnologies, Inc. | — | Biotechnology | Series D+ | $230.6M | $5.7B | 2021 |
| Sherlock Biosciences, Inc. | — | Biotech / Pharma | Series C | $112.8M | $1.7B | 2019 |
| Quanterix Corp | — | Other Technology | Series C | $71.8M | $194.1M | 2013 |
| Protillion Biosciences, lnc. | — | Biotech / Pharma | Series B | $19.0M | $256.3M | 2022 |
| Everest Biolabs, Inc. | — | Biotechnology | Series A | $4.3M | $10.3M | 2026 |
David Walt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Walt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Meister | 3 | 12 |
| Keith Crandell | 3 | 11 |
| David R. Walt | 2 | 5 |
| John Murphy | 1 | 17 |
| John Connolly | 1 | 14 |
| James Collins | 1 | 8 |
| Michael Rubin | 1 | 8 |
| Chen Yu | 1 | 7 |
| Andrea Jackson | 1 | 6 |
| John M. Connolly | 1 | 6 |
| Douglas Cole | 1 | 5 |
| Mark Angelino | 1 | 4 |
| Matthew Posard | 1 | 4 |
| Marijn Dekkers | 1 | 4 |
| PAUL M MEISTER | 1 | 4 |
| David Okrongly | 1 | 4 |
| Keith L. Crandell | 1 | 3 |
| Martin Madaus | 1 | 3 |
| VINIT NIJHAWAN | 1 | 3 |
| Malek Faham | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.